akorn inc
(AKRX:Consolidated Issue Listed on Nasdaq Glbl Slct Mrkt)
akorn inc (AKRX) Snapshot
|
Open
$14.51
|
Previous Close
$14.50
|
|
|
Day High
$14.90
|
Day Low
$14.47
|
|
|
52 Week High
07/9/12 - $16.87
|
52 Week Low
11/6/12 - $11.73
|
|
|
Market Cap
1.4B
|
Average Volume 10 Days
844.6K
|
|
|
EPS TTM
$0.40
|
Shares Outstanding
96.1M
|
|
|
EX-Date
08/29/91
|
P/E TM
37.1x
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
akorn inc (AKRX) Related Businessweek News
No Related Businessweek News Foundakorn inc (AKRX) Details
Akorn, Inc. engages in the manufacture and marketing of diagnostic and therapeutic ophthalmic pharmaceuticals products, hospital drugs, and injectable pharmaceuticals in the United States and internationally. It offers products in various specialty areas, including ophthalmology, antidotes, anti-infectives, pain management, anesthesia, and vaccines. The company’s Ophthalmic segment markets diagnostic products, including mydriatics and cycloplegics, anesthetics, topical stains, gonioscopic solutions, angiography dyes, and others primarily for use in the office setting. This segment also offers therapeutic products, such as antibiotics, steroids, steroid combinations, glaucoma medications, decongestants/antihistamines, and anti-edema medications to wholesalers, chain drug stores, and other national account customers; and non-pharmaceutical products, which include various artificial tear solutions, preservative-free lubricating ointments, and eyelid cleansers. In addition, the Ophthalmic segment provides a line of over-the-counter dry eye and other eye health products principally under the TheraTears brand name through a chain drug stores and big box retailers, as well as directly to optometrists, ophthalmologists, and other eye care practitioners and clinics. Its Hospital Drugs & Injectables segment provides a line of hospital drug and injectable pharmaceutical products comprising antidotes, anti-infectives, controlled substances for pain management and anesthesia, and other pharmaceutical products to hospitals through the wholesale distribution channel. The company’s Contract Services segment manufactures ophthalmic and injectable pharmaceutical products for third party pharmaceutical customers based on their specifications. It serves physicians, optometrists, hospitals, wholesalers, group purchasing organizations, retail pharmacy chains, and other pharmaceutical companies. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois.
akorn inc (AKRX) Top Compensated Officers
akorn inc (AKRX) Key Developments
Akorn, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, the company's revenues were $73.9 million compared with $51.7 million a year ago. The increase in consolidated revenue was driven by the sale of new products launched late in 2012, organic growth of established products and products re-launched in prior periods, and a full quarter's sales generated by Akorn India. Operating income was $18.6 million compared with $7.7 million a year ago. Income before income taxes was $16.3 million compared with $5.2 million a year ago. Net income was $10.8 million or $0.10 per diluted share compared with $3.1 million or $0.03 per diluted share a year ago. Net cash provided by operating activities was $6.9 million compared with $3.0 million a year ago. Purchases of property, plant and equipment was $2.7 million compared with $5.4 million a year ago. EBITDA was $21.8 million compared with $9.98 million a year ago. Adjusted EBITDA was $24.5 million compared with $19.9 million a year ago. Adjusted income before income taxes was $21.96 million compared with $17.9 million a year ago. Adjusted net income was $14.4 million or $0.13 per diluted share compared with $10.6 million or $0.10 per diluted share a year ago. Capital expenditures were $2.6 million, down from $5.4 million in the prior quarter. For the year 2013, the company expects total revenues in the range of $305 million - $315 million, total gross margin percentage in the range of 53% - 54%, intangible asset amortization expense of $7 million, income tax rate of 36%, GAAP net income in the range of $47 million - $50 million, GAAP net income per diluted share in the range of $0.42 - $0.44, adjusted net income in the range of $60 million - $62 million, adjusted net income per diluted share in the range of $0.53 - $0.55, and capital expenditures of $25 million.
Akorn, Inc. Presents at 12th Annual Needham Healthcare Conference, May-01-2013 01:40 PM. Venue: The Westin Grand Central Hotel, 212 East 42nd Street, New York, New York, United States.
Akorn, Inc. announced that they will report Q1, 2013 results at 9:00 AM, Eastern Standard Time on May 07, 2013
| Recently Viewed | |||
| AKRX:US | $14.83 USD | +0.33 |  |
| Company | Last | Change |
| Hi-Tech Pharmacal Co Inc | $32.95 USD | +0.68 |
| Lannett Co Inc | $12.19 USD | -0.10 |
| Sagent Pharmaceuticals Inc | $16.62 USD | +0.34 |
| Santarus Inc | $22.10 USD | +0.19 |
| ViroPharma Inc | $25.30 USD | -0.58 |
| View Industry Companies | ||
Industry Analysis
AKRX
Industry Average
| Valuation | AKRX | Industry Range |
| Price/Earnings | 37.4x |
|
| Price/Sales | 5.0x |
|
| Price/Book | 6.5x |
|
| Price/Cash Flow | 27.7x |
|
| TEV/Sales | 4.5x |
|
Post a JobJobs
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
- Northglenn, CO | Office DepotPosted: Mar 01
Sponsored Financial Commentaries
Sponsored Links
To contact AKORN INC, please visit www.akorn.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
